key: cord-0960177-4149qkrj authors: Fabiola, Martín-del-Campo; Neri, Ruvalcaba-Contreras; Alma L, Velázquez-Vidaurri; Alfonso M, Cueto-Manzano; Enrique, Rojas-Campos; Laura, Cortés-Sanabria; María C, Espinel-Bermúdez; Sandra O, Hernández-González; Arnulfo H, Nava-Zavala; Clotilde, Fuentes-Orozco; Luz, Balderas-Peña; Alejandro, González-Ojeda; Mario, Mireles-Ramírez title: Morbid Obesity Is Associated With Mortality And Acute Kidney Injury In Hospitalized Patients With Covid-19 date: 2021-09-03 journal: Clin Nutr ESPEN DOI: 10.1016/j.clnesp.2021.08.027 sha: 8edbe711e3abb55545cc983982985f6907ccc1a2 doc_id: 960177 cord_uid: 4149qkrj Background & Aims Mexico has one of the highest mortality rates by COVID-19 worldwide. This may be partially explained by the high prevalence of overweight/obesity found in general population; however, there is limited information in this regard. Furthermore, acute kidney injury (AKI) and need for renal replacement therapy (RRT) associated to obesity in patients with COVID-19 are still topics of discussion. Aim: To explore the association of obesity, particularly morbid obesity, with mortality and kidney outcomes in a Mexican population of hospitalized patients with COVID-19. Methods Retrospective cohort study of 773 patients with COVID-19 hospitalized in a tertiary-care teaching hospital in the Mexican state of Jalisco. Baseline body mass index was classified as: normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), obesity (30-39.9 kg/m2), and morbid obesity (≥40 kg/m2). AKI was diagnosed according to KDIGO clinical practice guidelines. Results At baseline, 35% of patients had overweight, 39% obesity and 8% morbid obesity. Patients with obesity were younger, more frequently women and with hypertension than normal weight and overweight patients. Frequency of complications in the univariate analysis were not significantly associated to obesity, however in the multivariate analysis (after adjusting for baseline clinical and biochemical differences), morbid obesity was significantly associated to an increased risk of AKI [OR=2.70 (1.01-7.26), p=0.05], RRT [OR=14.4 (1.46-42), p=0.02], and mortality [OR=3.54 (1.46-8.55), p=0.005]. Conclusions Almost half of the sample had obesity and morbid obesity. Morbid obesity was significantly associated to an increased risk of AKI, RRT and mortality in hospitalized patients with COVID-19. Province of China. The whole genome sequence was isolated on January 9, 2020 and was identified as severe acute respiratory syndrome coronavirus (SARS-CoV-2) (1). The rapid spread of the virus, produced the World Health Organization (WHO) to declare, by March 11, 2020 a worldwide pandemic (2) ; up to April 28, 2021 SARS-CoV-2 infection was confirmed in over 149 million subjects and caused over three million deaths worldwide, a mortality rate of two percent which varies between countries. Mexico is the 15th country with most cases (more than two-million) and third in deaths with >215 thousands, which means a mortality rate of nine percent (3). The latter makes Mexico one of the most hit countries by this pandemic, which may be partially explained by the elevated prevalence of risk factors, particularly overweight and obesity found in this country (75% among adult population) (4) . Obesity has been implicated as a risk factor for increased positivity testing and severe outcomes in patients with COVID-19 (5-7); however, its association with COVID-19 mortality has not been completely elucidated (8) . On the other hand, acute kidney injury (AKI) and the need for renal replacement therapy (RRT) associated to obesity in patients with COVID-19 remain scarcely explored, and the few reported data are contradictory (9, 10) . Moreover, there is no information about whether obesity, and particularly morbid obesity, is associated with AKI in this infectious disease. Therefore, the aim of this study was to explore the association of obesity, particularly morbid obesity, with mortality and kidney outcomes in a Mexican sample of hospitalized patients with COVID- 19 Definitions. Secondary infection was diagnosed when patients showed clinical symptoms or signs of pneumonia or bacteremia, and a positive culture of a new pathogen was obtained from lower respiratory tract specimens or blood samples after admission (12, 13) . AKI was diagnosed according to the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines (14) , and acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin Definition (15) . The illness severity was defined according to the quick Sequential Organ Failure Assessment (qSOFA) score (16) . Classification of body weight was made according to the OMS recommendation (17) as: normal weight (18.5 to 24.9 kg/m 2 ), overweight (25 to 29.9 kg/m 2 ), obesity (30 to 39.9 kg/m 2 ), and morbid obesity (≥40 kg/m 2 ). presented as mean ± standard deviation or median (interquartile range) and nominal ones as n (%). One-way ANOVA, Kruskal-Wallis or χ² tests were used to compare differences between body weight groups, as appropriate. A Pearson correlation analysis was performed between BMI and clinical and biochemical variables. A logistic regression analysis was performed to analyze mortality and renal outcomes according to the presence of obesity, in J o u r n a l P r e -p r o o f which significant baseline differences were used to adjust the analysis. A two-sided p<0.05 value was considered as statistically significant. One-thousand and ten patients were hospitalized during the study period; from these, 237 patients were excluded: 138 did not have anthropometric data, 88 had previous chronic kidney disease and 11 had a BMI <18.5 kg/m 2 . Thus, 773 were finally analyzed. Mean BMI of the whole sample was 30.9 ± 6.4 kg/m 2 . At baseline, almost half the studied sample had obesity; from this, morbid obesity was present in 8% ( Figure 1 ). Table 1 . Patients with obesity and morbid obesity were significantly younger, were more frequently women, and had higher frequency of hypertension, whereas only those with morbid obesity had higher respiratory rate than the other groups. No differences were found in other demographic and clinical variables. BMI has a positive correlation with respiratory rate, serum lymphocytes, hemoglobin, at admission, as well as with cardiac rate, lymphocytes and creatinine at discharge, wheras it was negatively correlated with D-dimer at admission (Supplementary Table 1) . Hospital stay length, presence of complications and mortality during hospitalization were not different between groups, except for the need of RRT, which was more common in patients with obesity and morbid obesity compared to the normal weight and overweight groups (Table 3) . In the multivariate analysis (Table 4) , after adjusting for baseline clinical and biochemical differences, morbid obesity was a significant predictor for AKI, need for RRT, and mortality; morbid obesity was also a significant predictor for respiratory failure. J o u r n a l P r e -p r o o f The current study found a high proportion of patients with overweight (35%) and obesity (47%) among those hospitalized by COVID-19. Reported prevalence of obesity in different meta-analysis was 31%-34% (18) (19) (20) , far below the observed in the current study. Our data support evidence of previous observations from Mexico reporting an obesity prevalence between 39.7% and 55.4% in patients with COVID-19 (21) (22) (23) . This is consistent with the J o u r n a l P r e -p r o o f fact that Mexico is second in the world in terms of obesity prevalence (24) : 75% of adult population suffering overweight/obesity (4). Many studies have shown an increased risk of mortality in patients with COVID-19 and obesity (25) (26) (27) (28) ; however, few have specifically analyzed if this issue displays a doseresponse effect (18) . Our study shows, that after adjusting for some important variables, the most severe grade of obesity significantly predicts higher mortality. In settings like ours, with higher prevalence of obesity in general population (24) and in hospitalized patients with COVID-19 than other countries (18) (19) (20) , the highest BMI was more clearly associated with increased mortality. Multiple mechanisms have been suggested to explain the association of obesity with mortality in COVID-19 patients, as association with low-grade chronic inflammatory status, higher expression of angiotensin converting enzyme binding system of SARS-CoV-2, and coexistence with other comorbidities (29) . On the other hand, AKI is one of the main complications in hospitalized patients with severe COVID-19 and is associated with increased mortality (30, 31) . Implications of obesity for development of AKI in patients with COVID-19 have been controversial (8, 9, 10, 23, 26) ; however, our results support the notion of a direct association, as patients with obesity and morbid obesity significantly increased serum creatinine concentrations at the end of the follow-up, compared to patients with overweight and normal weight. Moreover, those with the most severe obesity had increased risk for AKI and use of RRT in the multivariate analysis. Possible reasons of controversial results in previous studies could have been a lack of analysis by grades of obesity and exclusion of patients with previous diagnosis of chronic kidney disease, variables that were controlled in the present study. Obesity may increase the risk of AKI by several mechanisms not completely understood; however, dysregulation of fatty acids and carbohydrate metabolism, presence of comorbidities, oxidative stress and inflammation are likely the most important factors possibly associated to kidney injury (32) . In critically ill non-COVID-19 patients with AKI, obesity has shown a dual effect, and an "obesity survival paradox" has been proposed; nonetheless, it seems that negative outcomes associated with obesity are more relevant than the positive ones (32). In the current study, morbid obesity also predicted the development of respiratory failure, which is in agreement with the recognized presence of an obesity associated restrictive pulmonary function, characterized by increased respiratory rate and mild hypoxia secondary to ventilation-perfusion desynchronization (33, 34) . Finally, biochemical markers associated with inflammation were, unexpectedly, lower in patients with obesity and morbid obesity. Ferritin concentrations were significantly lower, and C-reactive protein and D-dimer had a non-significant trend to have lower levels in patients with obesity. These latter findings deserve further investigation, but they could be associated to the so-called "obesity paradox" (32, 35, 36) , in which the obesity-associated chronic inflammation may elicit an immune system strong response, which in turn, could help to recover faster from an infection. Our findings may help to understand the impact of obesity on mortality and kidney outcomes in hospitalized patients by COVID-19 as the current sample has a vast number of subjects exposed to this risk factor. Notwithstanding, the retrospective nature of the study and the characteristics of this single center population may limit validity. World Health Organization. Situation report World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 Encuesta Nacional de Salud y Nutrición 2018-19: análisis de sus principales resultados Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study Overweight/obesity as the potentially most important lifestyle factor associated with signs of pneumonia in COVID-19 The role of diabetes mellitus and obesity in COVID 19 patients The impact of obesity on COVID-19 complications: a retrospective cohort study Acute kidney injury in patients hospitalized with COVID-19 Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury Clinical management of COVID-19. Interim guidance (WHO/2019-nCoV/clinical/2020.5) Management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the Sepsis and septic shock: Guideline-based management Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline Acute respiratory distress syndrome: the Berlin Definition Assessment of Clinical Criteria for Sepsis for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) World Health Organization: Physical status: The use and interpretation of anthropometry Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis The Clinical Characteristics and Risk Factors of Severe COVID-19 Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: A cohort prospective study Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study Acute kidney injury in patients with severe COVID-19 in Mexico Obesity: global epidemiology and pathogenesis Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19 COVID-19-Associated Critical Illness-Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center Impact of comorbidities in Mexican SARS-CoV-2-positive patients: a retrospective analysis in a national cohort Obesity and COVID-19: what makes obese host so vulnerable? Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis Obesity, acute kidney injury and outcome of critical illness Pulmonary physiologic changes of morbid obesity Hypoxia and adipose tissue function and dysfunction in obesity The Obesity Paradox and the Role of Inflammation Reverse epidemiology, obesity and mortality in chronic kidney disease: modelling mortality expectations using energetics AHNZ, CFO, LMABP, AGO, and MMR made data curation and defined methodology of the protocol, FMC, NRC and ALVV perform data analysis, FMC, NRC and AMCM wrote the manuscript with support of ERC and ALVV. All authors discussed the results and contributed to the final manuscript.